ADACC NETWORK
Publications
Interested in collaborating with us?
Contact us at ADACC_Network@wfusm.edu
To present or publish a manuscript in collaboration with the ADACC Network or using ADACC data, please review our Policies and Procedures (P&P) and submit the completed ADACC Initial Analysis Proposal Form to the email above.
An ethical framework for the clinical use of Alzheimer’s disease biomarker testing
Published: 19 February 2026
Authors: Catherine E. A. Scipion, Michelle M. Mielke, Allyson C. Rosen, Suzanne E. Schindler & Jalayne J. Arias
Abstract
This paper proposes a conceptual ethical framework to guide decision-making around blood-based biomarker (BBM) testing for Alzheimer’s disease in primary care, where patients often present with cognitive impairment and multiple chronic conditions. Grounded in current evidence and ethical principles, it addresses clinical benefit, patient values, risk, and justice. Developed by a multidisciplinary team, the framework is illustrated through real-world case scenarios and highlights future research needs to support ethical implementation.
Proceedings of the Alzheimer's Diagnosis in Older Adults with Chronic Conditions (ADACC) Network Inaugural Annual Conference
Published: 09 March 2025
Abstract
The Alzheimer’s Disease in Older Adults with Chronic Conditions (ADACC) Network is funded by the National Institute on Aging as a U24 cooperative agreement. ADACC is an inclusive, multidisciplinary group across multiple institutions that is charged with the task of developing evidence-based strategies for the use and implementation of Alzheimer’s disease and related dementias (AD/ADRD) biomarkers among older adults with cognitive impairment and multiple chronic conditions (MCCs). This report summarizes highlights of the First Annual Symposium of ADACC, which was held in Winston-Salem, North Carolina, in April 2024. An overview of the ADACC network and goals were initially described, followed by a state of the science integrating biomarkers, AD/ADRD, and multiple chronic conditions. Multiple presentations on a variety of topics were featured, including the significance of MCCs in AD/ADRD, the effects of MCCs on Alzheimer’s blood-based biomarkers, the incorporation of AD/ADRD biomarkers into cancer care, the need to address racial and biomarker disparities, clinician and patient perspectives on plasma AD/ADRD biomarker testing, and ethical considerations. ADACC emphasized the importance of supporting emerging researchers and fostering a collaborative environment.